Several leading In Vitro Diagnostic (IVD) companies have posted their first-quarter results for 2026, showing mixed performance across revenue, profitability, and cash flow.

It can be seen from analysis on major blood grouping analyzer-related patent applications published in the 3 years from 2018 to 2021 that benefited from the basically stable original technologies of the industry; domestic enterprises have continuously increased R&D inputs, constantly improved technical innovation capability, made breakthroughs in many technologies, and developed a batch of core components of instruments with independent intellectual property rights through follow-on R&D strategy.

Quidel reported after the close of the market Thursday that its second quarter revenues rose 5 percent year over year due primarily to growth in the firm's rapid immunoassay business. Growth in molecular and specialized diagnostic solutions

Bio-Rad Laboratories reported after the close of the market Thursday that its second quarter revenues decreased approximately 1 percent year over year.

Coriell Life Sciences and global professional services firm KPMG said today that they have entered into a partnership with to provide pharmacogenomics data to clinicians at the point of care. Thermo Fisher Scientific is contributing genetic

Expedeon reported today an 18 percent increase in second quarter revenues driven in part by sales generated by recently acquired reagent maker TGR Biosciences.

Bio-Techne said today that its fiscal 2019 fourth quarter revenues rose 6 percent over fiscal Q4 2018.

Revenues from BD's medical segment were $2.31 billion during the quarter, an increase of 3 percent from $2.25 billion last year driven by medication management solutions, medication delivery solutions, and pharmaceutical systems units.

Genomenon has entered the Chinese market by forming a partnership with Shanghai Shanyi Biological Technology Co., a provider of sequencing interpretation, variant validation, and other molecular technology services.

Biotechnology company Freenome and ADC Therapeutics, an oncology drug discovery and development company, announced today that they have signed a biomarker development agreement.

Cancer Genetics today reported a 15 percent increase in second quarter revenues on improved performance by its core discovery services operations.

Aqualung Therapeutics said on Tuesday that it has been awarded a $225,000 grant from the National Institutes of Health to develop a panel of biomarkers, called CRIT-ICU, for stratifying patients at risk for acute respiratory distress syndrom